Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

RNA-seq

RNA-seq

RNA sequencing, or RNA-Seq, is a high-throughput sequencing technology used to study the transcriptome of a cell. Transcriptomics helps to interpret the functional elements of a genome and identify the molecular constituents of an organism. Additionally, it also helps in understanding the development of an organism and the occurrence of diseases.
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while microarray-based...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimizing In Vitro Efficacy Assessment of the Antisense Oligonucleotide Nusinersen in Human Cellular Models.

Pharmaceutics·2026

Same author

A call for preregistration of in vitro research : Pregistration as a tool to improve reproducibility and transparency.

EMBO reports·2026

Same author

Globo-H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer.

International journal of cancer·2026

Same author

Integrating Genomics, Radiomics, and Pathomics in Oncology: A Scoping Review and a Framework for AI-Enabled Surgomics.

Bioengineering (Basel, Switzerland)·2026

Same author

ZEB1 and Neural Stem Cells: Insights into Microglia-Conditioned Medium-Driven Neuroinflammation.

Cells·2025

Same author

Epigenomic alterations in psychiatric disorders and glioblastoma.

Epigenomics·2025

Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026

Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026

Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026

Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026

Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026

Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Rapid Colorimetric Assays to Qualitatively Distinguish RNA and DNA in Biomolecular Samples

Rapid Colorimetric Assays to Qualitatively Distinguish RNA and DNA in Biomolecular Samples

Published on: February 4, 2013

Current Technologies for RNA-Directed Liquid Diagnostics.

Maria Victoria Martinez-Dominguez¹, Alja Zottel², Neja Šamec²

¹Clinic for Neurosurgery, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.

|October 23, 2021

Summary

This summary is machine-generated.

RNA-based liquid diagnostics show great promise, but readiness for routine oncology use is a concern. This review assesses current RNA diagnostic technologies, their clinical and economic viability, and future investment strategies for precision medicine.

Keywords:

cancer biomarker circulating free nucleic acids exosome liquid biopsy

More Related Videos

Simple Bulk Readout of Digital Nucleic Acid Quantification Assays

Simple Bulk Readout of Digital Nucleic Acid Quantification Assays

Published on: September 24, 2015

Visual Detection of Multiple Nucleic Acids in a Capillary Array

Visual Detection of Multiple Nucleic Acids in a Capillary Array

Published on: November 15, 2017

Related Experiment Videos

Last Updated: Jun 27, 2026

Rapid Colorimetric Assays to Qualitatively Distinguish RNA and DNA in Biomolecular Samples

Rapid Colorimetric Assays to Qualitatively Distinguish RNA and DNA in Biomolecular Samples

Published on: February 4, 2013

Simple Bulk Readout of Digital Nucleic Acid Quantification Assays

Simple Bulk Readout of Digital Nucleic Acid Quantification Assays

Published on: September 24, 2015

Visual Detection of Multiple Nucleic Acids in a Capillary Array

Visual Detection of Multiple Nucleic Acids in a Capillary Array

Published on: November 15, 2017

Area of Science:

Biotechnology
Molecular Diagnostics
Precision Medicine

Background:

Liquid nucleic acid-based diagnostics offer significant potential, particularly in oncology.
The COVID-19 pandemic highlighted RNA technologies but raised concerns about routine diagnostic readiness.
Controversies and awareness surrounding RNA diagnostics necessitate a thorough review of their current status.

Purpose of the Study:

To review the status quo of RNA-based liquid diagnostics in oncology.
To benchmark available RNA diagnostic assays based on technical background and applicability.
To analyze technology readiness, clinical context, economic aspects, and performance of RNA diagnostics.

Main Methods:

Summarized technical background of existing RNA-based liquid diagnostic assays.
Benchmarked assays against each other regarding clinical readiness, economic factors, and performance.
Investigated market trends, focusing on early disease detection and therapy success surveillance.
Analyzed biotechnology investment activities to identify future economic strategies.

Main Results:

RNA diagnostics present substantial potential but face challenges in routine clinical implementation.
Comparative analysis of assays revealed varying technology readiness levels and performance metrics.
The preventive care market, especially for early detection, is a key area for development.
Biotechnology investment trends suggest specific strategies for economic success in this sector.

Conclusions:

RNA-based liquid diagnostics are a rapidly developing field with significant potential in precision medicine.
A comprehensive understanding of technological, clinical, and economic factors is crucial for successful implementation.
This review provides a reference for navigating the interplay of technology, clinical utility, and economic viability in RNA diagnostics.